Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: The antiproliferative effect of first-line long acting somatostatin analogs (SSA) in advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) was shown in the PROMID and the CLARINET trials. Efficacy data in pancreatic NETs (PanNETs) with Ki-67 ≥ 10% are limited.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Merola E
Authors: Merola E, Alonso Gordoa T, Zhang P, Al-Toubah T, Pelle E,
Keywords: Pancreatic NET, Somatostatin Analogs, Grade 2 and 3, Safety, Efficacy,
Introduction: G3 NETs are rare tumors with poorly defined prognosis and management.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: de Mestier L, Lamarca A, Hernando-Cubero J, Alonso Gordoa T, Cros J,
Keywords: grade 3, prognosis, treatment, alkylating agents,
Introduction: MEN1, DAXX, ATRX, and PI3K/AKT/mTOR pathway genes are frequently mutated in pNETs. Sunitinib is approved and widely used in the metastatic setting but unfortunately, no validated predictive biomarker has been identified to guide therapy yet. The SUNEVO phase II trial of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumours (GETNE) trial combined the pro-drug of EVO under SUN-induced hypoxic conditions.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Santos M, Lanillos J, Lopez C, Alonso Gordoa T, Benavent M,
Keywords: pancreatic, neuroendocrine, mutations, correlation,